Induction of beta cell differentiation in human cells

• US 6,911,324 B2
• Filed: 10/18/2001
• Issued: 06/28/2005
• Est. Priority Date: 10/18/2001
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Itkin-Ansari, Pamela, Levine, Fred, Gouty, Dominique
• Primary Examiner(s): Ketter, James
• Assistant Examiner(s): LAMBERTSON, DAVID A
• Application Number:
  US10/041,845
• Publication Number:
  US 20030077259A1
• Time in Patent Office: 1,349 Days
• Field of Search: 435/41, 435/70.1, 435/70.4, 435/440, 435/455, 435/325, 435/366
• US Class Current: 435/70.1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 2501/335 Glucagon; Glucagon-like peptide [GLP]; Exendin
• CPC Class Codes: C12N 2501/60 Transcription factors
• CPC Class Codes: C12N 2503/02 Drug screening
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2510/04 Immortalised cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention provides methods for inducing insulin gene expression in cultured pancreas cells, the method comprising contacting a culture of endocrine pancreas cells expressing a PDX-1 gene and a NeuroD/BETA2 gene with a GLP-1 receptor agonist, wherein the cells have been cultured under conditions such that the cells are in contact with other cells in the culture, thereby inducing insulin gene expression in the cells. The invention also provides high throughput screening methods for modulators of β-cell function, stable cultures of cells made by the methods of the invention, and methods of treating a human subject using the methods of the invention.

Claims

1. A method for inducing insulin gene expression in cultured pancreatic cells, the method comprising the steps of:

(i) expressing a recombinant NeuroD/BETA2 polynucleotide and a recombinant PDX-1 polynucleotide in pancreatic cells that have been cultured under conditions such that the pancreatic cells are in contact with other cells in the culture; and

(ii) contacting the cells with a GLP-1 receptor agonist, thereby inducing insulin gene expression in the pancreatic cells.

2. The method of claim 1, wherein the GLP-1 receptor agonist is a GLP-1 analog.

3. The method of claim 1, wherein the cells are cultured as aggregates in suspension.

4. The method of claim 1, the cells express a recombinant telomerase gene.

5. The method of claim 1, wherein the GLP-1 receptor agonist has an amino acid sequence of a naturally occurring peptide.

6. The method of claim 5, wherein the GLP-1 receptor agonist is GLP-1, exendin-3, or exendin-4.

7. The method of claim 1, wherein the cells express a recombinant oncogene.

8. The method of claim 7, wherein the cells express more than one recombinant oncogene.

9. The method of claim 1, wherein the cells are β

-cells.

10. The method of claim 9, wherein the β

-cells are β

lox5 cells.

11. The method of claim 9, wherein the β

-cells are human β

-cells.

12. An endocrine pancreas β

-cell comprising a recombinant PDX-1 polynucleotide and a recombinant NeuroD/BETA2 polynucleotide.

13. The β

-cell of claim 12, wherein the β

-cell is a human β

-cell.

14. The β

-cell of claim 12, wherein the β

-cell expresses a recombinant telomerase gene.

15. The β

-cell of claim 12, wherein the β

-cell expresses a recombinant oncogene.

16. The β

-cell of claim 15, wherein the β

-cell expresses more than one recombinant oncogene.

17. A stable culture of pancreatic cells, wherein the pancreatic cells are in contact with other cells in the culture and cultured as aggregates in suspension, wherein the pancreatic cells express a recombinant PDX-1 polynucleotide and a recombinant NeuroD/BETA2 polynucleotide, and wherein insulin gene expression is stimulated in the pancreatic cells when exposed to an effective amount of a GLP-1 receptor agonist.

18. The culture of claim 17, wherein the GLP-1 receptor agonist is a GLP-1 analog.

19. The culture of claim 17, wherein the cells express a recombinant telomerase gene.

20. The culture of claim 17, wherein the GLP-1 receptor agonist has an amino acid sequence of a naturally occurring peptide.

21. The culture of claim 20, wherein the GLP-1 receptor agonist is GLP-1, exendin-3, or exendin-4.

22. The culture of claim 17, wherein the cells express a recombinant oncogene.

23. The culture of claim 22, wherein the cells express more than one recombinant oncogene.

24. A stable culture of pancreatic cells, wherein the pancreatic cells are in contact with other cells in the culture, wherein the pancreatic cells express a recombinant PDX-1 polynucleotide and a recombinant NeuroD/BETA2 polynucleotide, and wherein insulin gene expression is stimulated in the pancreatic cells when exposed to an effective amount of a GLP-1 receptor agonist, and wherein the pancreatic cells are β

-cells.

25. The culture of claim 24, wherein the β

-cells are β

lox5 cells.

26. The culture of claim 24, wherein the β

-cells are human β

-cells.

27. The culture of claim 24, wherein the GLP-1 receptor agonist is a GLP-1 analog.

28. The culture of claim 24, wherein the cells express a recombinant telomerase gene.

29. The culture of claim 24, wherein the GLP-1 receptor agonist has an amino acid sequence of a naturally occurring peptide.

30. The culture of claim 29, wherein the GLP-1 receptor agonist is GLP-1, exendin-3, or exendin-4.

31. The culture of claim 24, wherein the cells express a recombinant oncogene.

32. The culture of claim 31, wherein the cells express more than one recombinant oncogene.